Search Results - "Fonder, A L"

Natural history of t(11;14) multiple myeloma by Lakshman, A, Alhaj Moustafa, M, Rajkumar, S V, Dispenzieri, A, Gertz, M A, Buadi, F K, Lacy, M Q, Dingli, D, Fonder, A L, Hayman, S R, Hobbs, M A, Gonsalves, W I, Hwa, Y L, Kapoor, P, Leung, N, Go, R S, Lin, Y, Kourelis, T V, Lust, J A, Russell, S J, Zeldenrust, S R, Kyle, R A, Kumar, S K

“…Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma…”
Get full text

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains by Sidana, S, Tandon, N, Dispenzieri, A, Gertz, M A, Buadi, F K, Lacy, M Q, Dingli, D, Fonder, A L, Hayman, S R, Hobbs, M A, Gonsalves, W I, Hwa, Y L, Kapoor, P, Kyle, R A, Leung, N, Go, R S, Lust, J A, Russell, S J, Zeldenrust, S R, Rajkumar, S V, Kumar, S K

“…Hematologic response criteria in light chain (AL) amyloidosis require the difference in involved and uninvolved free light chains (dFLC) to be at least 5…”
Get full text

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma by Tandon, N, Rajkumar, S V, LaPlant, B, Pettinger, A, Lacy, M Q, Dispenzieri, A, Buadi, F K, Gertz, M A, Hayman, S R, Leung, N, Go, R S, Dingli, D, Kapoor, P, Lin, Y, Hwa, Y L, Fonder, A L, Hobbs, M A, Zeldenrust, S R, Lust, J A, Gonsalves, W I, Russell, S J, Kumar, S K

“…We analyzed the utility of Revised International staging system (RISS) in an unselected cohort of newly diagnosed multiple myeloma (NDMM; cohort 1), and…”
Get full text

Natural history of t by Kyle, R A, Rajkumar, S V, Hobbs, M A, Russell, S J, Hayman, S R, Leung, N, Lacy, M Q, Kumar, S K, Alhaj Moustafa, M, Kourelis, T V, Dispenzieri, A, Buadi, F K, Dingli, D, Gertz, M A, Lin, Y, Gonsalves, W I, Fonder, A L, Lust, J A, Zeldenrust, S R, Kapoor, P, Lakshman, A, Go, R S, Hwa, Y L

“…Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma…”
Get full text

Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma by Lakshman, Arjun, Singh, Preet Paul, Rajkumar, S. Vincent, Dispenzieri, Angela, Lacy, Martha Q., Gertz, Morie A., Buadi, Francis K., Dingli, David, Hwa, Yi Lisa, Fonder, Amie L., Hobbs, Miriam, Hayman, Suzanne R., Zeldenrust, Steven R., Lust, John A., Russell, Stephen J., Leung, Nelson, Kapoor, Prashant, Go, Ronald S., Lin, Yi, Gonsalves, Wilson I., Kourelis, Taxiarchis, Warsame, Rahma, Kyle, Robert A., Kumar, Shaji K.

“…Experience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE‐like regimens:…”
Get full text

Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials by Lakshman, Arjun, Abeykoon, Jithma P., Kumar, Shaji K., Rajkumar, S. Vincent, Dingli, David, Buadi, Francis K., Gonsalves, Wilson I., Leung, Nelson, Dispenzieri, Angela, Kourelis, Taxiarchis V., Go, Ronald S., Lacy, Martha Q., Hobbs, Miriam A., Lin, Yi, Warsame, Rahma, Lust, John, Fonder, Amie L., Hwa, Yi L., Hayman, Suzanne R., Russell, Stephen J., Kyle, Robert A., Gertz, Morie A., Kapoor, Prashant

“…Outside of clinical trials, experience with daratumumab‐based combination therapies (DCTs) using bortezomib (V)/lenalidomide (R)/pomalidomide (P), and…”
Get full text